CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 102 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $152 | -63.5% | 17,468 | -73.7% | 0.02% | -71.2% |
| Q4 2022 | $416 | -99.9% | 66,329 | -33.0% | 0.05% | +13.0% |
| Q3 2022 | $347,000 | +89.6% | 99,029 | +59.2% | 0.05% | +70.4% |
| Q2 2022 | $183,000 | -69.4% | 62,194 | -67.6% | 0.03% | -66.2% |
| Q1 2022 | $598,000 | -23.1% | 192,244 | -16.5% | 0.08% | -18.4% |
| Q4 2021 | $778,000 | -19.3% | 230,258 | -12.9% | 0.10% | 0.0% |
| Q3 2021 | $964,000 | +69.1% | 264,224 | +102.2% | 0.10% | +53.1% |
| Q2 2021 | $570,000 | -32.6% | 130,672 | -29.9% | 0.06% | -54.3% |
| Q1 2021 | $846,000 | -3.5% | 186,317 | +21.9% | 0.14% | -2.1% |
| Q4 2020 | $877,000 | +126.6% | 152,797 | -22.6% | 0.14% | +217.8% |
| Q4 2019 | $387,000 | +64.0% | 197,290 | +327.9% | 0.04% | +40.6% |
| Q3 2019 | $236,000 | -22.1% | 46,103 | +9.0% | 0.03% | -5.9% |
| Q2 2019 | $303,000 | -56.3% | 42,285 | -32.3% | 0.03% | -10.5% |
| Q3 2018 | $693,000 | +13.8% | 62,500 | -5.6% | 0.04% | +2.7% |
| Q4 2017 | $609,000 | -50.0% | 66,200 | -56.2% | 0.04% | -55.4% |
| Q3 2017 | $1,218,000 | – | 151,100 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |